| Document |
Document Title |
|
WO/2023/211883A1 |
One aspect of the invention is any compound, or salt thereof, described herein. Another aspect is a method of treating a disease, disorder, or symptom thereof, in a subject, comprising administration to the subject of a compound, or salt...
|
|
WO/2022/162014A1 |
The present invention concerns aza-cryptophanes, processes for preparation thereof, and their uses, in particular as in vivo diagnostic tools when complexing a hyperpolarized noble element, or in nanoemulsions.
|
|
WO/2022/060036A1 |
The present invention provides a novel compound capable of improving the light-emitting efficiency, stability, and lifespan of an element, an organic electronic element using same, and an electronic device comprising same.
|
|
WO/2021/131927A1 |
The present invention is a photosensitive composition containing a color material A including a pigment, a pigment derivative B and a dispersant C. The pigment derivative B includes a pigment derivative B1 having a molar absorption coeff...
|
|
WO/2020/243155A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an es...
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/091054A1 |
The invention provides a novel production method for an isoquinoline-6-sulfonamide derivative that is useful as a medicinal drug, and also provides an intermediate for use in the method. The invention is the 1,4-diazocane compound repres...
|
|
WO/2019/226925A1 |
Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal d...
|
|
WO/2019/075259A1 |
The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1,...
|
|
WO/2018/233326A1 |
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...
|
|
WO/2018/183198A1 |
Methods for making an arylomycin ring of formula t or salts or solvates thereof, wherein R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R5, R10 and Pg1 are as defined herein.
|
|
WO/2018/149419A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...
|
|
WO/2018/070773A1 |
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure can provide a low driving voltage and excellent luminous efficiency by comprising a specific combinat...
|
|
WO/2018/043829A1 |
Provided are a compound represented by a specific formula, a core-shell dye comprising a core comprising the compound and a shell enclosing the core, a photosensitive resin composition comprising the core-shell dye, and a color filter ma...
|
|
WO/2017/173048A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.
|
|
WO/2017/156471A1 |
The disclosure provides for compounds having immunoproteasome inhibitory activity, and pharmaceutical compositions made thereof. The disclosure further provides for the use of the compounds and compositions in treating various diseases a...
|
|
WO/2017/156074A1 |
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or medi...
|
|
WO/2017/116272A1 |
The invention relates to the field of the organic chemistry and, in particular to a method for preparing a compound of formula (I) or (II), and/or a mixture of isomers thereof, wherein R is -Alk, -AlkN(Alk)2, -AlkN(Ar)2, -AlkNAlkAr, -Alk...
|
|
WO/2017/084630A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...
|
|
WO/2017/084629A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...
|
|
WO/2017/003188A1 |
The present invention relates to: a novel compound which has an outstanding luminescent ability; and an organic electroluminescent element having improved properties including high luminous efficiency, low drive voltage and long lifespan...
|
|
WO/2016/193482A1 |
Processes for preparation of 7-chloro-1-methyl-5-phenyl-1,5-dihydro- benzo[b][1,4]diazepine-2,4-dione (Clobazam) are provided. The present invention also relates to the novel intermediates and its use in preparation of clobazam.
|
|
WO/2015/188107A1 |
Synthesis of novel and unique PAMAM (poly-amidoamine) polymers. PAMAM polymers can be grown by systematic alternation between ethylenediamine (EDA) and methacrylate. By taking advantage of the alternating terminal ends, successive genera...
|
|
WO/2015/175770A1 |
Largazole analogues, methods of making the same, and methods of using the same, are described.
|
|
WO/2015/157057A1 |
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
|
|
WO/2014/201073A9 |
The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.
|
|
WO/2015/070204A1 |
Provided herein are compounds of the formula (I) : as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containin...
|
|
WO/2014/183015A1 |
Compositions are provided for selectively inhibiting bacterial proteasome. Also provided are methods for assaying the compositions, methods for treating bacterial infection, and methods for inducing apoptosis in tumor cells using the com...
|
|
WO/2014/081886A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type (1) signal peptidase (SpsB), an essential p...
|
|
WO/2014/048692A1 |
The present invention relates to a method for producing metathesis products comprising contacting metathesis starting materials under metathesis conditions with a metathesis catalyst, wherein the metathesis catalyst is employed in an amo...
|
|
WO/2013/188750A2 |
The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors.
|
|
WO/2012/167171A2 |
The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.
|
|
WO/2012/114342A1 |
The present invention provides soluble complexes of flumazenil, methods for the preparation thereof, pharmaceutical compositions comprising same and use of said compositions for alleviating or counteracting the various types of hypersomn...
|
|
WO/2012/070015A9 |
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...
|
|
WO/2012/051413A1 |
Provided are methods for reversing the effects of agents used for muscular immobilization and/or loss of consciousness and/or loss of pain perception. The method comprises administering a composition comprising acyclic CB[n]-type compoun...
|
|
WO/2011/137190A1 |
Embodiments of the invention provide a tetraamido macrocyclic ligand catalytic activator bound to a carbon containing support. When combined with an oxidant, such as a peroxy compound, the carbon supported catalytic activator is a long-l...
|
|
WO/2011/107248A1 |
The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present inv...
|
|
WO/2011/076674A1 |
The invention relates to polymers (P) of amides, imides, amides-imides or their derivates. The polymer (P) comprising recurring units (I) of one or more structural formula(e):-A-B-C-D- (I), wherein, A and C, identical or different from e...
|
|
WO/2011/069045A2 |
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.
|
|
WO/2011/058193A1 |
The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound ...
|
|
WO/2011/050068A2 |
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The inv...
|
|
WO/2011/034051A1 |
Compounds represented by general formula (1) or salts thereof. In general formula (1), A is an aromatic hydrocarbon ring or an aromatic heterocycle (with the ring and the heterocycle being optionally substituted); R1 to R11 may be the sa...
|
|
WO/2010/081731A2 |
The present invention relates to syringolin A derivatives, the use of the syringolin A derivatives for prophylaxis and treatment of neurodegenerative diseases and proliferative diseases such as cancer, pharmaceutical compositions contain...
|
|
WO/2010/071212A1 |
Provided is a method for capping the end of a polymer by means of a carbodimide composition without freeing an isocyanate compound. This method uses as the polymer end-capping agent a compound which has one carbodimide group and which co...
|
|
WO/2010/017272A2 |
A method of treating neurological diseases, like Alzheimer's Disease by administering a compound that activates protein kinase C and inhibits histone deacetylases to an individual suffering from the neurological disease. The method utili...
|
|
WO/2009/152051A1 |
The present invention provides a method of synthesis of a macrocyclic compound known as a potent inhibitor of a protease produced by the hepatitis C virus (HCV). Inhibition of the viral protease blocks assembly of mature viral particles ...
|
|
WO/2009/070164A1 |
Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In a...
|
|
WO/2009/037642A1 |
Disclosed are heterocyclic scaffolds useful, for example, for solid-phase organic synthesis of combinatorial libraries and methods for the preparation thereof. Also disclosed are libraries, including combinatorial libraries, and methods ...
|
|
WO/2008/117796A1 |
The invention relates to mutilin derivatives represented by the general formula (I) which are useful as antimicrobial agent against multidrug-resistant bacteria; and intermediates for the production of the same. In the general formula (I...
|
|
WO/2008/116302A1 |
The present invention relates to novel compounds of the formula (I), wherein R'-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of ca...
|
